Role Overview & Key Functions:The Executive Director, Brand Lead – Endometrial Cancer (EC) is a senior commercial leader responsible for U.S. brand strategy, launch readiness, performance planning, and lifecycle management for Karyopharm’s EC program. This is a unique opportunity to shape the U.S. commercial strategy for a potential new treatment approach in endometrial cancer at a pivotal moment for Karyopharm. The Brand Lead will help translate late-stage science into a launch-ready commercial strategy, build the market with urgency and discipline, and lead cross-functional efforts focused on improving outcomes for patients with advanced or recurrent endometrial cancer.The Executive Director will operate as the commercial lead for the EC disease area, driving alignment across Sales, Marketing, Market Access, Market Analytics, Regulatory, Legal, Commercial Operations, Medical Affairs, and Finance. This individual will shape long-term strategic direction while establishing the launch priorities, operating discipline, and cross-functional execution required to prepare the organization for a high-quality U.S. launch.Operating in a lean biotech environment, the Brand Lead will bring strategic clarity, decisive leadership, and strong enterprise collaboration to ensure the organization is field-ready, access-ready, customer-ready, and evidence-aligned to establish a differentiated position in the evolving gynecologic oncology landscapeRESPONSIBILITIES:Brand Strategy & PlanningOwn the U.S. EC brand strategy and multi-year commercial roadmap; deliver an annual Brand Plan/AOP with clear objectives, KPIs, milestones, and investment choices aligned to franchise and corporate priorities.Define and evolve positioning, message platform, and customer value proposition; translate clinical and real-world evidence into differentiated, compliant claims and communications.Lead lifecycle planning and strategic scenario work (e.g., competitive response, biomarker-driven opportunities, combination strategies, line-of-therapy expansion opportunities, and treatment sequencing dynamics), partnering with cross-functional leaders to evaluate options and trade-offs.Lead biomarker strategy in partnership with Medical Affairs, Market Access, Diagnostics/External Partners, and Field teams, with attention to tumor testing workflows, education needs, and barriers to patient identification.Launch Strategy and LeadershipDrive U.S. EC launch strategy and readiness from pivotal data readout through launch execution, defining launch milestones, critical path, and cross-functional workstreams including positioning, messaging, field readiness, access readiness, omnichannel activation, and patient support.Lead the U.S. EC Launch Team and governance cadence, driving timely decisions, risk and issue escalation, and integrated execution across Sales, Medical, Market Access/HEOR, Analytics, Regulatory, Legal/Compliance, and Commercial Operations to ensure an on-time, high-quality launch.Customer Strategy, Segmentation & Field EnablementDevelop customer segmentation and targeting strategy across key stakeholders, including gynecologic oncologists, medical oncologists, academic cancer centers, community oncology practices, integrated delivery networks, and key accounts.Translate strategy into customer engagement plans, field execution priorities, promotional programs, and pull-through tools.Serve as senior marketing lead to Sales leadership and the field organization; ensure tight alignment on priorities, messaging, execution standards, and feedback loops.Performance Management, Analytics & Investment OptimizationMaintain accountability for brand performance versus plan; establish operating rhythms and dashboards to monitor demand, share, customer engagement, and execution quality.Integrate insights from market research, secondary data, competitive intelligence, and field feedback into continuous optimization and forward-looking strategy.Partner with Finance and Forecasting to manage budget, resource prioritization, and scenario planning; make data-driven recommendations to maximize ROI and business impact.Cross-Functional LeadershipLead, coach, and develop direct reports and/or matrix team members, creating a high-accountability, collaborative, and mission-driven launch culture.Partner with Market Access/HEOR to shape value strategy and pull-through plans; ensure brand strategy reflects coverage realities, mitigates access barriers, and supports pathway and formulary objectives.Provide commercial input to evidence generation and insights planning in collaboration with Medical Affairs and HEOR to address adoption barriers and strengthen stakeholder confidence.Present brand strategy, performance, risks, and recommendations to Executive Leadership; proactively identify issues and propose mitigation plans.Candidate Profile & Requirements:QUALIFICATIONS:BS/BA required; advanced degree preferred (MBA, PharmD, PhD, MPH, or equivalent)12+ years of commercial biopharmaceutical experience, including 7+ years in oncology marketingLaunch, major lifecycle event, and/or new indication experience in oncology; solid tumor experience preferredExperience in endometrial cancer, gynecologic oncology, or related oncology markets preferredProven success developing brand strategy and delivering commercial resultsStrong understanding of U.S. market access, reimbursement, and oncology treatment landscapesExperience leading cross-functional teams in a fast-paced biotech environmentExceptional strategic thinking, analytical, communication, and executive presentation skillsDemonstrated ability to influence senior stakeholders and drive alignment across functionsAt Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $270K - $315K USD.Our Value Proposition:This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.Learn more at Karyopharm Therapeutics.
